Atlas Trials

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Clinical trial NCT04866836 · TERMINATED

Trial details

NCT number
NCT04866836
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Cholangiocarcinoma
Start date
2020-10-01
Primary completion
2021-12-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.